NZ594603A - Hybrid polypeptides with selectable properties - Google Patents
Hybrid polypeptides with selectable propertiesInfo
- Publication number
- NZ594603A NZ594603A NZ59460306A NZ59460306A NZ594603A NZ 594603 A NZ594603 A NZ 594603A NZ 59460306 A NZ59460306 A NZ 59460306A NZ 59460306 A NZ59460306 A NZ 59460306A NZ 594603 A NZ594603 A NZ 594603A
- Authority
- NZ
- New Zealand
- Prior art keywords
- bio
- active peptide
- peptide hormone
- polypeptide
- exendin
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Disclosed is a hybrid polypeptide, said polypeptide comprising a first bio-active peptide hormone module covalently linked to a second bio-active peptide hormone module; wherein: the first bio-active peptide hormone is selected from exendin-4 with the sequence HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS or an analogue or derivative of exendin-4 or fragment thereof that stimulates insulin secretion, and wherein the analogue, derivative or fragment has at least 90% amino acid sequence identity to exendin-4; the second bio-active peptide hormone reduces body weight and comprises amylin, an amylin analogue having at least 80% sequence identity to amylin, or KCNTATCVLGRLSQELHRLQTYPRTNTGSNTY; the bio-active peptide hormone modules are covalently attached using a Gly linker 1 to 30 residues long; the first bio-active peptide hormone module is located at the N-terminal end of the hybrid polypeptide; and the C-terminal end of the hybrid polypeptide is amidated. The disclosed polypeptide is also used in the manufacture of a medicament for treating diabetes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20166405A | 2005-08-11 | 2005-08-11 | |
| US11/206,903 US8076288B2 (en) | 2004-02-11 | 2005-08-17 | Hybrid polypeptides having glucose lowering activity |
| US11/301,744 US7723471B2 (en) | 2004-02-11 | 2005-12-12 | Pancreatic polypeptide family motifs, polypeptides and methods comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ594603A true NZ594603A (en) | 2013-03-28 |
Family
ID=48575094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ59460306A NZ594603A (en) | 2005-08-11 | 2006-08-11 | Hybrid polypeptides with selectable properties |
Country Status (3)
| Country | Link |
|---|---|
| ES (1) | ES2537062T3 (en) |
| IL (1) | IL231953A0 (en) |
| NZ (1) | NZ594603A (en) |
-
2006
- 2006-08-11 NZ NZ59460306A patent/NZ594603A/en not_active IP Right Cessation
- 2006-08-11 ES ES10012149.0T patent/ES2537062T3/en active Active
-
2014
- 2014-04-06 IL IL231953A patent/IL231953A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL231953A0 (en) | 2014-05-28 |
| ES2537062T3 (en) | 2015-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10696726B2 (en) | Insulin-incretin conjugates | |
| AU2017216533B2 (en) | Improved peptide pharmaceuticals | |
| RU2378285C2 (en) | Hybrid polypeptides with selectable properties | |
| US10232020B2 (en) | Incretin-insulin conjugates | |
| AU2013323669B2 (en) | Insulin analog dimers | |
| JP6392123B2 (en) | CTP-based insulin analog for diabetes treatment | |
| CA2891929C (en) | Improved peptide pharmaceuticals | |
| IL184429A (en) | Heterologous fusion proteins comprising a glp-1 compound fused to another polypeptide, pharmaceutical formulations comprising them and use thereof in the preparation of medicaments | |
| NZ596778A (en) | Glucose-regulating polypeptides and methods of making and using same | |
| CN101993485A (en) | Peptide analog homologous dimer capable of accelerating insulin secretion and application thereof | |
| NZ596787A (en) | Growth hormone polypeptides and methods of making and using same | |
| EP2376521A1 (en) | Amide-based insulin prodrugs | |
| JP2013533864A (en) | Single-chain insulin agonist with high activity for insulin receptor | |
| AU2011245980A1 (en) | Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability | |
| WO2011163460A1 (en) | Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor | |
| JP6811190B2 (en) | Protease-resistant lipid-added GLP-1 analog | |
| CN113105561B (en) | Preparation method and application of double-target fusion protein | |
| WO2023148366A1 (en) | Glp-1 and glucagon dual agonist peptides with improved biological stability | |
| NZ594603A (en) | Hybrid polypeptides with selectable properties | |
| WO2017210077A1 (en) | Single chain insulin prodrugs | |
| WO2024098718A1 (en) | Novel long-acting polypeptide compound, composition, and use thereof | |
| Tang et al. | Structure and function relationships of three novel hGHRH-GGC analogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: AMYLIN PHARMACEUTICALS, LLC, US Free format text: OLD OWNER(S): AMYLIN PHARMACEUTICALS, INC. Owner name: ASTRA ZENECA PHARMACEUTICALS LP, US Free format text: OLD OWNER(S): AMYLIN PHARMACEUTICALS, INC. |
|
| ERR | Error or correction |
Free format text: THE MISSING INVENTOR HAS BEEN ADDED (1159674, LEWIS, DIANA Y; 1159677, D'SOUZA, LAWRENCE J; 1187478, HANLEY, MICHAEL R; 1187479, JODKA, CAROLYN M; 1187481, SOARES, CHRISTOPHER J; 1187482, GHOSH, SOUMITRA S; 1187484, PARKES, DAVID G; 1187485, MACK, CHRISTINE M; 1187486, FOROOD, BEHROUZ BRUCE; 3061908, LEVY, ODILE ESTHER, 9360 TOWNE CENTRE DRIVE, SAN DIEGO CALIFORNIA 92121, US) Effective date: 20130304 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 AUG 2013 BY CPA GLOBAL Effective date: 20130704 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 AUG 2016 BY AJ PARK Effective date: 20131030 |
|
| LAPS | Patent lapsed |